ATRX and ovarian carcinoma: Our study further opens a therapeutic axis in several HRR proficient cancer models where in Ovarian cancer (50 patients among 584 cases, https://www.cbioportal.org/study/summary?id=ov_tcga), breast cancer (20 patients among 2173 cases, https://www.cbioportal.org/study/summary?id=brca_metabric) and castration resistant prostate cancer (73) RAD54 expression is increased due to gene amplification.